Standard Biotools Inc   (LAB)
Other Ticker:  
Price: $2.9000 $0.01 0.346%
Day's High: $2.9692 Week Perf: 5.84 %
Day's Low: $ 2.89 30 Day Perf: -2.03 %
Volume (M): 241 52 Wk High: $ 3.16
Volume (M$): $ 698 52 Wk Avg: $1.95
Open: $2.94 52 Wk Low: $0.92

 Market Capitalization (Millions $) 228
 Shares Outstanding (Millions) 79
 Employees -
 Revenues (TTM) (Millions $) 105
 Net Income (TTM) (Millions $) -84
 Cash Flow (TTM) (Millions $) 68
 Capital Exp. (TTM) (Millions $) 4

Standard Biotools Inc
based on the information available on their website and other sources, here is an extensive description of Standard Biotools Inc:Standard Biotools Inc is a biotechnology company founded in 1999 and headquartered in Taiwan.
The company is primarily engaged in the development, manufacture, and distribution of high-quality life science research tools, including biochemicals, enzymes, antibodies, and kits, for academic, pharmaceutical, and biotech companies worldwide.
Standard Biotools has a wide range of product offerings for various research applications, including molecular biology, protein research, cell biology, and immunoassays.
Some of the company's popular products include DNA and RNA extraction kits, PCR reagents, protein purification kits, monoclonal antibodies, and ELISA kits.
The company has a strong focus on research and development, which has helped them bring several innovative products to market.
They have a team of experienced scientists who work on developing new technologies and improving existing products.
Standard Biotools also collaborates with academic and research institutions to develop new products and offer custom solutions.
In addition to its research tools business, Standard Biotools has a contract research organization (CRO) division that provides preclinical services for drug discovery research.
Their CRO services include in vivo pharmacology, in vitro assays, and pharmacokinetics and toxicology services.
Overall, Standard Biotools Inc is a reputable and established biotech company with a wide range of high-quality research tools and CRO services.
They have a strong focus on R&D and are committed to developing innovative solutions to meet the needs of their customers in the life sciences industry.

   Company Address: 2 Tower Place South San Francisco 94080 CA
   Company Phone Number: 266-6000   Stock Exchange / Ticker: NASDAQ LAB
   LAB is expected to report next financial results on November 08, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Astrotech Corp

Astrotech Corp Shines Amidst Industry Challenges with Impressive 1625% Revenue Growth in 2023

The stock market is a dynamic and ever-changing landscape that often presents investors with an array of opportunities. One company that has recently caught the attention of many investors is Astrotech Corp. In the fourth quarter of the earnings season for 2023, the company reported a staggering 1625% year-on-year revenue advance, reaching $0.41 million. This is an impressive achievement that showcases the company's robust growth.
However, it is important to note that Astrotech Corp also reported losses widening at $-1.44 million during the same period. While this might raise concerns for some investors, it is essential to look at the bigger picture. Astrotech Corp operates in the laboratory analytical instruments sector, which is currently facing headwinds due to receding orders and fading revenue. Against this backdrop, Astrotech Corp's performance stands out as a bright spot in a challenging industry.

Kewaunee Scientific Corporation

Kewaunee Scientific Corporation Reports Declining Revenue in First Quarter of 2024, But Remains Profitable

Kewaunee Scientific Corporation, a prominent Laboratory Analytical Instruments company, recently released its financial results for the fiscal first quarter of 2024. Despite a decline in revenue, the company managed to achieve profitability, indicating certain positive developments for shareholders. This article will analyze the financial results and examine how they may impact the company's future.
1. Revenue Decline:
Kewaunee Scientific Corporation experienced a decrease in revenue by -2.412% to $48.91 million compared to the previous year. This decline can pose challenges, as it signifies a potential slowdown in sales growth. However, it is essential to consider the reasons behind the drop in revenue, aiming to identify any temporary or fixable issues affecting Kewaunee's performance.

Agilent Technologies Inc

Agilent Technologies Inc. Battling Steep Decline in Income per Share, but Shows Signs of Recovery

Agilent Technologies Inc. experienced a modest increase in its stock price over the last five trading days, rising by 1.16%. However, this gain must be put into perspective, as the year-to-date performance of the stock is at -19.31%. Investors should evaluate this recent uptick in light of the overall downward trend in the company's stock value.
One of the contributing factors to this decline is a reduction in earnings per share. Agilent Technologies Inc. saw a significant decrease of -65.45% in earnings per share, falling to $0.38. Additionally, the company witnessed a revenue decrease of -2.678% to $1.67 billion compared to the previous fiscal period.

Pressure Biosciences Inc

Pressure Biosciences Inc Reports Mixed Financial Results for Q2 2023, with Modest Revenue Growth

Pressure Biosciences Inc's (PBIO) financial results for the second quarter of 2023 have left analysts and investors with mixed emotions. While the company reported a surge in net deficit and a decline in inventories and accounts receivable, they managed to achieve modest revenue growth. This article will analyze PBIO's financial performance in the context of the overall Laboratory Analytical Instruments industry and the company's stock performance.
Financial Results Analysis:
PBIO reported a per-share deficit of $-0.57 for the second quarter of 2023, an increase from -$0.32 in the same quarter a year ago. Sequentially, the deficit also rose from -$0.46 per share from the prior quarter. This decline in profitability raises concerns among investors and underscores the need for PBIO to address its financial challenges.

Accelerate Diagnostics Inc

Lab Instruments Giant, Accelerate Diagnostics Inc, Faces Revenue Drop and Mounting Losses in Recent Fiscal Period

Accelerate Diagnostics Inc (AXDX) has reported an increase in losses for the fiscal time-frame ending June 30, 2023, primarily due to weak demand. The net loss per share advanced to $-2.97 from $-0.24, indicating a significant decline in profitability. Additionally, the company's revenue witnessed a decline of 27.506%, amounting to $2.80 million compared to $3.86 million in the previous year.
In comparison to the previous quarter, there was a slight decrease in revenue by 0.462%, from $2.81 million. Furthermore, there was a surge in loss per share from $-0.17. These figures highlight the ongoing struggles faced by Accelerate Diagnostics Inc in maintaining a stable financial performance.
For the financial time-frame ending June 30, 2023, Accelerate Diagnostics Inc recorded a net loss of $-32.735 million, surpassing the loss of $-18.523 million reported a year ago. This reflects a continuing trend of declining profitability for the company.


Standard Biotools Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Š 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com